Shining a light on the FCGR locus; genomic analysis of germline and somatic lesions
)
Monoclonal antibody (mAb) immunotherapy is becoming standard in the treatment of cancer, particularly for B-cell lymphoma patients, however responses are variable and relapse is common. Thus, the molecular mechanisms that underpin resistance needs to be defined.